Wall Street's luke-warm stance toward the retail sector should not prevent you from considering Kohl's Corporation (NYSE: KSS) as a retail play.
Kohl's has successfully broadened its offerings to the point where it is now a leading, moderately-priced retail chain. Kohl's offerings in apparel, shoes, accessories, cosmetics, home furnishings and housewares now hold their own against primary competitor JC Penney Company, Inc. (NYSE: JCP).
Further, regional market adaptations of store inventory keep KSS in-tune with what consumers want in a particular geographic area. Also, a computerized mark-down optimization program is likely to improve margins for clearance items/lines: there's no sense cutting the price of an item before a store has to, in order to sell it. Not surprisingly, analysts' channel checks consistently report a department store chain that knows what its customers want, and that prices items fairly, in well-run stores.
Also, look for Kohl's to slightly expand its customer base, but its target market of married women ages 25-50 should continue to drive impressive same store sales gains. Kohl's has about 820 stores and expects to have 1,200 by F2011. The Reuters F2008/F2009 EPS consensus estimates for KSS are: $3.64 to $4.22.
The qualifiers? As always, analysts are watching the consumer discretionary spending statistic in light of continued elevated gasoline prices, and a possible slowing U.S. economy. Hence, if gasoline sails past $4 per gallon in 2008, it undoubtedly hurts Kohl's results. But absent that scenario, look for Kohl's to remain a leader in its segment. KSS's modest p/e of 13 also lowers the stock's risk/return ratio.
The First Call mean rating for KSS is: Buy. [25 firms.] Mean 2007 target: $71.00. [high: $103, low: $47.]
Stock Analysis: Kohl's is a moderate-risk stock not suitable for low-risk investors. Don't buy Kohl's shares if your portfolio already contains an adequate retail component. Investors with an investment horizon longer than 2 years should be rewarded from KSS's shares. Sell / Stop Loss if you were to consider buying this stock: $37.
Last updated: February 13, 2012: 01:57 AM
Hot Stocks
DailyFinance Headlines
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
Benzinga Headlines
- Michigan Consumer Sentiment Index Drops
- Don't Bank on Barclays
- GSV Capital Punished for Expanding Facebook Investment
- Chesapeake Gently Lets Go of Gas
- How to Profit off Addicts
TheFlyOnTheWall.com Headlines
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger

